NCT06705036 Differential Study of Invasive Pituitary Adenomas in the Sellar and Cavernous Sinus Regions
| NCT ID | NCT06705036 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Zhongshan Hospital |
| Condition | Pituitary Tumor |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2025-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2024-11-01 with a primary completion date of 2025-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study involves collecting paired tumor samples from intrasellar and cavernous sinus regions of 20 invasive pituitary tumor patients, preserving them at -80°C for quality multi-omics analysis. Proteomics and transcriptomics are employed to identify molecular differences, while imaging data (MRI/CT) assesses tumor morphology and invasion. In vitro experiments and mechanistic studies validate key findings, exploring how regional molecular differences affect tumor behavior. Data integration combines multi-omics and imaging features to uncover biomarkers and pathways associated with invasiveness and regional specificity, with statistical analysis ensuring significance and reliability.
Eligibility Criteria
Inclusion Criteria: 1. Invasive pituitary tumors involving the cavernous sinus 2. Retrospective inclusion of patients who have signed informed consent forms for the donation of biological samples and health-related information 3. Age range: 18-80 years 4. Subjects are willing to participate in this study Exclusion Criteria: 1. Non-invasive pituitary tumors 2. Pregnant or breastfeeding 3. Other conditions deemed unsuitable for participation in this clinical trial as assessed by the physician
Contact & Investigator
Tao Xie
STUDY DIRECTOR
Fudan University
Frequently Asked Questions
Who can join the NCT06705036 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Pituitary Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06705036 currently recruiting?
Yes, NCT06705036 is actively recruiting participants. Contact the research team at xie.tao@zs-hospital.sh.cn for enrollment information.
Where is the NCT06705036 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06705036 clinical trial?
NCT06705036 is sponsored by Shanghai Zhongshan Hospital. The principal investigator is Tao Xie at Fudan University. The trial plans to enroll 20 participants.